Lupin

    LUPIN
    Pharma
    ₹2095.00
    price as of 11/9/2026, 5:27:57 pm

    Market cap ₹95,797 Cr

    P/E
    17.35
    Day range
    ₹2,058.00 – ₹2,108.50
    52-week range
    ₹1,900.00 – ₹2,529.50
    Volume
    6.22 L
    Open
    ₹2,064.00
    Prev close
    ₹2,077.80
    Promoters pledged 1.2% of their shares
    52-week range, adjusted for splits and bonuses
    ₹1,900₹2,529.5
    28 Oct 202516 Jul 2026
    Index membership & F&O
    NIFTY 200NIFTY 500NIFTY MIDCAP 150NIFTY HEALTHCARENIFTY PHARMAF&O lot 425

    Price history

    6M change -10.65%RSI (14) 28.1 OversoldSMA 20 · 50 overlaid

    Price & delivery on the exchange

    NSE bhavcopy to 11 Sept 2026 · delivery 59.8% today vs 56.6% average · BSE close ₹2,096

    1 Apr23 Apr15 May5 Jun24 Jun15 Jul3 Aug21 Aug11 Sept₹1,950₹2,100₹2,250₹2,400₹2,5500%25%50%75%100%
    • Delivery
    • NSE close
    • BSE close

    High delivery with a rising price suggests buyers holding rather than trading the move.

    Futures & options

    NSE F&O close, 11 Sept 2026 · options expiring 29 Sept 2026

    Short covering
    Near-month future
    ₹2,096.5
    Change
    +0.69%
    Basis over spot
    +₹1.50
    Futures OI (shares)
    83.2 L
    OI change
    -0.56%
    Put-call ratio
    0.69
    Max pain
    ₹2,160
    Resistance (call OI)
    ₹2,300
    Support (put OI)
    ₹2,100
    Lot size
    425

    Open interest by strike

    Calls open above (resistance) and puts below (support), in shares

    172018401900196020202080214022002260232023802440250002.0 L4.0 L6.0 L8.0 Lspot
    • Call OI
    • Put OI

    Futures open interest and price

    Near-month future, day by day since collection began

    The daily history builds from each close.

    Key metrics

    P/E (TTM)
    16.2
    EPS (TTM)
    ₹127.94
    ROE (FY26)
    27.0%
    ROCE (latest year)
    30%
    Dividend yield
    0.87%

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +18.9%
    Profit 3Y CAGR
    +128.6%
    Revenue YoY (Jun 2026)
    +32.1%
    Profit YoY (Jun 2026)
    +16.1%
    Operating margin
    30.0%
    Net margin
    17.1%

    Revenue, profit & margin - quarterly

    Bars in ₹ crore (a loss shows red); line is operating margin

    Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Jun 20260 Cr2.5K Cr5.0K Cr7.5K Cr10.0K Cr0%9%18%27%36%
    • Revenue
    • Net profit
    • Operating margin

    Who owns the company

    Shareholding as of Jun 2026

    • Promoter
    • DII
    • FII
    • Public

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-8.0K Cr-4.0K Cr0 Cr4.0K Cr8.0K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26-12%0%12%24%36%15%

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); line is debt-to-equity

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 20260 Cr6.0K Cr12.0K Cr18.0K Cr24.0K Cr0.0x0.2x0.4x0.6x0.8x
    • Equity
    • Debt
    • Debt / equity

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
    Sales5,0395,1974,9615,6005,6735,7685,6676,2687,0487,1687,4758,277
    Expenses4,1214,1593,9644,3594,3324,4124,3464,5414,7064,9064,9895,827
    Operating Profit9181,0389971,2411,3401,3561,3211,7272,3412,2622,4862,450
    OPM %18%20%20%22%24%24%23%28%33%32%33%30%
    Other Income402929684254577990-3129130
    Interest8174716871678992108115120110
    Depreciation248257457248257271393299317313447453
    Profit before tax6307364989931,0551,0718961,4162,0071,5221,9282,017
    Tax %21%16%26%19%19%20%13%14%26%22%24%30%
    Net Profit4956193688068598597821,2211,4851,1811,4691,417
    EPS in Rs₹10.76₹13.47₹7.89₹17.58₹18.69₹18.74₹16.92₹26.69₹32.36₹25.73₹31.94₹30.95

    From company filings, updated 11 Sept 2026. Consolidated figures where the company reports them.Information only, not investment advice.

    Strengths, risks & growth

    Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

    Strengths

    • Company has delivered good profit growth of 37.0% CAGR over last 5 years
    • Company has been maintaining a healthy dividend payout of 17.1%
    • Company's working capital requirements have reduced from 46.4 days to 28.0 days

    Risks

    None flagged by the checklist.

    Compounded Sales Growth

    10 Years
    +7%
    5 Years
    +13%
    3 Years
    +19%
    TTM
    +28%

    Compounded Profit Growth

    10 Years
    +10%
    5 Years
    +37%
    3 Years
    +140%
    TTM
    +61%

    Stock Price CAGR

    10 Years
    +3%
    5 Years
    +16%
    3 Years
    +23%
    1 Year
    +5%

    Return on Equity

    10 Years
    +10%
    5 Years
    +13%
    3 Years
    +22%
    Last Year
    +29%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderSept 2025Dec 2025Mar 2026Jun 2026Change
    Promoter46.89%46.89%46.85%46.85%0.00 pp
    FII20.50%21.50%21.70%22.42%+0.72 pp
    DII26.56%25.58%25.32%24.65%-0.67 pp
    Government0.00%0.00%0.00%0.00%0.00 pp
    Public6.06%6.04%6.13%6.08%-0.05 pp

    Filed with NSE for Jun 2026: promoters 46.85%, public 53.15% · XBRL filing

    Analysts & fund holdings

    52%
    52% recommend buy
    33 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E17.4 vs 46.4
    Sector P/B5.84
    Beta0.74

    Who holds the shares, quarter by quarter

    Mutual funds 14.84% (-2.09 pp)
    Mar 25
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    • Promoters46.9%
    • Foreign institutions22.4%
    • Mutual funds14.8%
    • Insurance6.9%
    • Other domestic institutions2.9%
    • Retail4.9%
    • Others1.2%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    HDFC Balanced Advantage Fund1.24%1.16%-0.13 pp
    HDFC Flexi Cap Fund1.06%0.94%+0.10 pp
    HDFC Large Cap Fund1.00%2.53%-0.33 pp
    Mirae Asset Large & Midcap Fund0.90%1.97%-0.04 pp
    Mirae Asset Midcap Fund0.68%3.29%-0.17 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    High
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.

    Corporate actions

    • dividend
      ₹18.00

      Dividend - Rs 18 Per Share

      17 Jul 2026
      ex-date
    • dividend
      ₹12.00

      Dividend - Rs 12 Per Share

      25 Jul 2025
      ex-date
    • dividend
      ₹8.00

      Dividend - Rs 8 Per Share

      16 Jul 2024
      ex-date
    • dividend
      ₹4.00

      Dividend - Rs 4 Per Share

      14 Jul 2023
      ex-date
    • dividend
      ₹4.00

      Dividend - Rs 4 Per Share

      14 Jul 2022
      ex-date
    • dividend
      ₹6.50

      Dividend - Rs 6.50 Per Share

      27 Jul 2021
      ex-date
    • dividend
      ₹6.00

      Annual General Meeting/Dividend - Rs 6 Per Share

      3 Aug 2020
      ex-date
    • dividend
      ₹5.00

      Annual General Meeting/Dividend - Rs 5 Per Share

      29 Jul 2019
      ex-date
    • dividend
      ₹5.00

      Annual General Meeting/Dividend Rs 5/- Per Share

      30 Jul 2018
      ex-date
    • dividend
      ₹7.50

      Annual General Meeting/Dividend - Rs 7.50 Per Share

      24 Jul 2017
      ex-date
    • dividend
      ₹7.50

      Annual General Meeting/ Dividend -Rs 7.50/- Per Share

      25 Jul 2016
      ex-date
    • dividend
      ₹7.50

      Annual General Meeting/ Dividend - Rs 7.50/- Per Share

      14 Jul 2015
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting / Final Dividend - Rs 3/- Per Share

      21 Jul 2014
      ex-date
    • dividend
      ₹3.00

      Interim Dividend - Rs 3/- Per Share

      13 Feb 2014
      ex-date
    • dividend
      ₹4.00

      Annual General Meeting / Dividend - Rs 4/- Per Share

      29 Jul 2013
      ex-date
    • dividend
      ₹3.20

      Annual General Meeting And Dividend Rs.3.20 Per Share

      13 Jul 2012
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting And Dividend Rs.3/- Per Share

      18 Jul 2011
      ex-date
    • split
      ₹2.00

      Face Value Split From Rs.10/- To Rs.2/-

      27 Aug 2010
      ex-date
    • dividend
      ₹13.50

      Annual General Meeting And Dividend Rs.13.50 Per Share

      19 Jul 2010
      ex-date
    • other
      Not available — not reported in this filing

      Agm/Div-Rs.12.50 Pr Share

      20 Jul 2009
      ex-date

    Bulk & block deals

    Large deals reported to NSE in this stock
    DateClientTypeQuantityPrice
    12 Sept 2025—Short sale36—

    Deals of more than 0.5% of shares (bulk), large single trades (block) and short sales, as NSE reports them.

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation about participating in the Analyst/Institutional Investors Meet.

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP.

    Company Update
    Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015- ESG Rating

    ESG Rating by Crisil ESG Ratings & Analytics Ltd.

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Intimation of allotment of 30967 equity shares under ESOP.

    Company Update
    Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating

    ESG Rating by ESG Risk Assessment and Insights Limited.

    Company Update
    Exclusive License Agreement With Visus Therapeutics, Inc. U.S.A.

    VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.

    Company Update
    Announcement under Regulation 30 (LODR)-Demise

    Intimation of Demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company.

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Lupin Announces Approval from U.S. FDA for Pitolisant Tablets.

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Transcript of Q1 FY2027 Earnings Conference Call

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation about participating in the Analyst/Institutional Investors Meet.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Copies of Newspaper publication in respect of Unaudited Financial Results of the Company for the quarter ended June 30, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Link of Audio recording of the Earnings Call-Q1 FY27.

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Investor Presentation (Revised) - Q1 FY27 Results

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Investor Presentation- Q1 FY2027

    Filed with BSE (scrip 500257); the last 45 days. Documents open at bseindia.com.

    Documents

    Annual reports

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 12 Feb 2025 (unaudited). View the source filing. Figures are as filed and are not investment advice.